Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Alizarin Red S
ID: ALA5277614
Max Phase: Preclinical
Molecular Formula: C14H8NNaO7S
Molecular Weight: 335.29
Associated Items:
ID: ALA5277614
Max Phase: Preclinical
Molecular Formula: C14H8NNaO7S
Molecular Weight: 335.29
Associated Items:
Canonical SMILES: O=C1c2ccccc2C(=O)c2c1cc(NS(=O)(=O)[O-])c(O)c2O.[Na+]
Standard InChI: InChI=1S/C14H9NO7S.Na/c16-11-6-3-1-2-4-7(6)12(17)10-8(11)5-9(13(18)14(10)19)15-23(20,21)22;/h1-5,15,18-19H,(H,20,21,22);/q;+1/p-1
Standard InChI Key: RNIUBLGLQXSMFJ-UHFFFAOYSA-M
Molfile:
RDKit 2D 24 25 0 0 0 0 0 0 0 0999 V2000 2.9342 -1.4979 0.0000 Na 0 0 0 0 0 15 0 0 0 0 0 0 -3.2145 0.4122 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.4999 0.8245 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.7881 0.4125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.7881 -0.4125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -2.4981 -0.8243 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -3.2145 -0.4162 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.0734 0.8251 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.3587 0.4125 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -0.3587 -0.4126 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.0734 -0.8252 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.3539 0.8234 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.0688 0.4109 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 1.0706 -0.4100 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 0.3590 -0.8267 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0 -1.0734 1.6503 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 -1.0734 -1.6503 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 0.3539 1.6486 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.7834 0.8235 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 1.7852 -0.8227 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0 2.4999 -0.4100 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0 3.2145 -0.8227 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.0873 0.3045 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 2.9124 0.3045 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0 3 2 2 0 4 3 1 0 5 4 2 0 6 5 1 0 2 7 1 0 7 6 2 0 4 8 1 0 9 8 1 0 10 9 2 0 11 10 1 0 5 11 1 0 9 12 1 0 13 12 2 0 14 13 1 0 15 14 2 0 10 15 1 0 8 16 2 0 11 17 2 0 12 18 1 0 13 19 1 0 14 20 1 0 20 21 1 0 21 22 1 0 21 23 2 0 21 24 2 0 M CHG 2 1 1 22 -1 M END
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 335.29 | Molecular Weight (Monoisotopic): 335.0100 | AlogP: 1.09 | #Rotatable Bonds: 2 |
Polar Surface Area: 141.00 | Molecular Species: ACID | HBA: 6 | HBD: 4 |
#RO5 Violations: ┄ | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: -1.97 | CX Basic pKa: ┄ | CX LogP: 2.10 | CX LogD: -0.42 |
Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.41 | Np Likeness Score: 0.59 |
1. Yang GJ, Tao F, Zhong HJ, Yang C, Chen J.. (2022) Targeting PGAM1 in cancer: An emerging therapeutic opportunity., 244 [PMID:36215859] [10.1016/j.ejmech.2022.114798] |
Source(1):